ASX Announcements Archive - Regeneus Ltd

2018

30 July 2020 – US Patent Progenza

30 July 2020 – Update on licensing Progenza in Japan_0

30 July 2020 – RGS European Patent for ASX Final

30 July 2020 – Results of AGM 2018_ASX

30 July 2020 – Regeneus receives R&D tax incentive of $2.4m

30 July 2020 – Regeneus Announces Successful Results in Acne Study

30 July 2020 – Regeneus AGM

30 July 2020 – Regeneus 2018 Half-Year Results and Business Update

30 July 2020 – Regeneus 2018 Full-Year Results and Business Update

30 July 2020 – R&D Loan Facility

30 July 2020 – Progenza granted Advanced Therapy Medicinal Product

30 July 2020 – Presentation Half Year Results

30 July 2020 – Positive trial results of Progenza for knee osteoarthritis_0

30 July 2020 – Notice of AGM_0

30 July 2020 – Japanese Patent Office to grant patent for cancer vaccine technology

30 July 2020 – FY18 Presentation

30 July 2020 – Chinese Patent RGS

30 July 2020 – Cancer Vaccine ph1 results

30 July 2020 – ASX Announce_JM to present at AusBiotech JM

30 July 2020 – Appendix4G

30 July 2020 – Appendix 3Y

30 July 2020 – App 3Y

30 July 2020 – 181122 – FY18 Regeneus AGM Presentation for ASX

30 July 2020 – 180723 – Response to ASX

30 July 2020 – 2018 Chairman’s Address AGM_ASX

2017

30 July 2020 – US Patent For Sygenus

30 July 2020 – Sygenus lasting effect

30 July 2020 – Results AGM

30 July 2020 – Regeneus to attend Business Mission to Japan

30 July 2020 – Regeneus – Q2 2017 Update

30 July 2020 – Regeneus – Final NoM for ASX and Proxy Sample

30 July 2020 – RD Tax Incentive_2017

30 July 2020 – Progenza patent granted in Japan_Final for ASX

30 July 2020 – New Director joins Regeneus Board of Directors

30 July 2020 – Japan First_1

30 July 2020 – Half Year 2017 Announcement for ASX

30 July 2020 – Chinese patent for acne_28_03_2017_ASX

30 July 2020 – BioChina – Regeneus

30 July 2020 – Appendix 4G

30 July 2020 – AGM Presentation

30 July 2020 – AGC milestone payment for STEP trial

30 July 2020 – 172301 – RGS Receives Upfront Payment From AGC

30 July 2020 – 170822 – FY17 Presentation

30 July 2020 – 170518 – Progenza – positive results for STEP trial for OA

30 July 2020 – 170222 – RGS 2017 Half Year Results

30 July 2020 – 170222 – RGS 2017 Half Year Results Presentation

30 July 2020 – 2017 AGM

2016

30 July 2020 – 161229 – RGS AGC Collaboration Progenza

30 July 2020 – 161218 – Trading Halt Request

30 July 2020 – 161019 – Results AGM

30 July 2020 – 161019 – Chairmans Address AGM

30 July 2020 – 161019 – CEO Presentation AGM

30 July 2020 – 160914 – NOM Proxy

30 July 2020 – 160912 – RGS Receives RD Tax Incentive refund of $2.7m

30 July 2020 – 160824 – FY16 Results

30 July 2020 – 160824 – FY16 Results Presentation

30 July 2020 – 160809 – Date of AGM

30 July 2020 – 160805 – ASX Price Query

30 July 2020 – 160801 – RGS European Patent To Grant

30 July 2020 – 160517 – ARC Linkage Grant Progress Research

30 July 2020 – 160516 – Enrolment Complete Positive Safety Progenza Trial

30 July 2020 – 160309 – ASX Price Query

30 July 2020 – 160229 – Half Year Report

30 July 2020 – 160112 – Positive Safety First Cohort Progenza

2015

30 July 2020 – 151215 – Patent Granted Cancer Vaccine Technology

30 July 2020 – 151207 – RGS Present Austrade

30 July 2020 – 151207 – Corporate Presentation Austrade

30 July 2020 – 151126 – Canine Cancer Trial SASH

30 July 2020 – 151124 – High Potency Cells

30 July 2020 – 151111 – Allogeneic Technology Patent Granted

30 July 2020 – 151109 – Results AGM

30 July 2020 – 151109 – Chairman Address

30 July 2020 – 151109 – AGM Presentation

30 July 2020 – 151105 – Positive Results Equine CryoShot

30 July 2020 – 151102 – CryoShot Animal Health Partner

30 July 2020 – 151027 – RGS Patient Treated Cancer Trial

30 July 2020 – 151013 – RGS RD Tax Rebate

30 July 2020 – 151008 – RGS NOM Proxy

30 July 2020 – 150904 – RGS Restricted Securities

30 July 2020 – 150902 – RGS AGM Date

30 July 2020 – 150831 – RGS FY15 Announcement

30 July 2020 – 150831 – FY15 Results Pres

30 July 2020 – 150810 – RGS Progenza Trial First Patient

30 July 2020 – 150525 – RGS Approval Personalised Cancer Immunotherapy Trial

30 July 2020 – 150422 – RGS Receives Progenza Ethics Approval

30 July 2020 – 150407 – RGS PRG Manufacture Milestone

30 July 2020 – 150323 – RGS ARM 25032015

30 July 2020 – 150309 – RGS Positive Preclinical Results PRG

30 July 2020 – 150223 – RGS Dr Glen Richards

30 July 2020 – 150219 – RGS Half Year Results Announcement

2014

30 July 2020 – Successful $3M private placement

30 July 2020 – SPP Announcement

30 July 2020 – Share Purchase Plan

30 July 2020 – RGS raises capital through Placement and SPP

30 July 2020 – RGS Ethics approval for procurement for off-the-shelf OA treatment

30 July 2020 – Cleansing Notice

30 July 2020 – Chairman’s Address to Shareholders

30 July 2020 – AFL HiQCell Approval 270814

30 July 2020 – 141219 – RGS Patent Granted Cryopreserved Stem Cells

30 July 2020 – 141126 – RGS New Japanese Laws Take Effect

30 July 2020 – 141124 – RGS Concludes Strategic Review

30 July 2020 – 141114 RGS Acne Treatment Patent Granted

30 July 2020 – 141028 – RGS Results AGM

30 July 2020 – 141028 – RGS Presentation Shareholders AGM 0

30 July 2020 – 141009 – RGS Response to ABC

30 July 2020 – 140925 – RGS NOM Sample Proxy

30 July 2020 – 140925 – R&D Tax Incentive

30 July 2020 – 140923 – HiQCell in Singapore

30 July 2020 – 140911 – Kvax launch

30 July 2020 – 140821 – RGS Cryosite Announcement

30 July 2020 – 140819 – RGS Patient Registry Update

30 July 2020 – 140731 – RGS Market Update

30 July 2020 – 140708 – RGS secures exclusive worldwide rights for new human cancer vaccine

30 July 2020 – 140630 – Press Release – RGS enters agreement for US marketing trial of Kvax

30 July 2020 – 140514 – RGS Regeneus stem cells show promise for chronic neuropathic pain sufferers

30 July 2020 – 140406 – RGS Publication of Kvax cancer vaccine paper shows safety and efficacy in animals

30 July 2020 – 140404 – RGS Manufacturing of Kvax canine cancer vaccine in the US

30 July 2020 – 140326 – Regeneus to present at Regenerative Medicine Investor Day March 26 in New York

30 July 2020 – 140326 – Press Release – Patient Registry Announcement

30 July 2020 – 140122 – Regeneus ASX Announcement Lonza Manufacturing Agreement

30 July 2020 – 101114 RGS Board Management Changes

2013

30 July 2020 – Press Release – New laws in Japan

30 July 2020 – PRESS RELEASE – Canine cancer vaccine gets green light in USA

30 July 2020 – Notice of Annual General Meeting

30 July 2020 – BBY Life Sciences RGS Investor Presentation

30 July 2020 – ASX spotlight

30 July 2020 – 131127 – Regeneus (RGS) results of AGM

30 July 2020 – 131030 – Regeneus HiQCell stem cell therapy available in Melbourne Announcement

30 July 2020 – 131021 – RGS PRX301R Shares Sample

30 July 2020 – 131008 – Regeneus Ltd OSCARS Clinical Trial Results Announcement

27 November 2013 – ASX Announcement – Chairman’s address

See recent ASX announcements

[/vc_column_inner][/vc_row_inner]